Featured News

On April 8 and April 9, the Celiac Disease Foundation is sponsoring the Columbia University Celiac Disease Center International Symposium on Celiac Disease.

Join us at the Columbia University Celiac Connect Continuing Medical Education- April 1, and UChicago Neurological and Psychological Implications in Celiac Disease- April 23.

Researchers found that children initially diagnosed with potential celiac disease had a high risk of developing celiac disease.

A few highlights from research studies published in peer-reviewed journals in the last few months are products of the research grants CDF awarded.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

A study from the University of Chicago has demonstrated that B-cells are required for the development of villous atrophy (intestinal damage) in celiac disease. This finding provides support for the exploration of B-cell–directed therapies for the treatment of celiac disease.

Researchers found higher rates of skin disease in patients with celiac disease compared to controls, including increased risks for eczema, psoriasis, urticaria, vitiligo, acne, and alopecia areata.

We are pleased to share the video recording of Dr. Jocelyn Silvester discussing what you need to know about pediatric celiac disease now and in the future.

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.